hrs4r
 I want to donate
Firma
RAFAEL FUENTES-RASPALL
Position
Investigador/a Post-doctoral – R2
Postdoctoral Researchers – R2

Projectes

Codi oficial: 2021 SGR 01463 - ONCORFIM Girona Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER.
Codi oficial: 6822ZB3KJ Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER.

Publicacions

Bonet M, González D, Baquedano JE, García E, Altabas M, Casas F, Feltes N, Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jové J, Lozano J, Maldonado X, Mases J, Membrive I, Paredes S, Roselló À, Sancho G, Mira M

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 1017-1023 dx.doi.org/10.1007/s12094-022-03005-4
Serdà-Ferrer BC, Sanvisens A, Fuentes-Raspall R, Puigdemont M, Farré X, Vidal-Vila A, Rispau-Pagès M, Baltasar-Bagué A, Marcos-Gragera R

Significantly reduced incidence and improved survival from prostate cancer over 25 years.

Bmc Public Health, 2023, 23, 2552-2552 dx.doi.org/10.1186/s12889-023-17440-7
Jurado-Bruggeman, D, Munoz-Montplet, C, Hernandez, V, Saez, J, Fuentes-Raspall, R

Impact of the dose quantity used in MV photon optimization on dose distribution, robustness, and complexity

MEDICAL PHYSICS, 2022, 49, 648-665 dx.doi.org/10.1002/mp.15389
Muñoz-Montplet C, Fuentes-Raspall R, Jurado-Bruggeman D, Agramunt-Chaler S, Onsès-Segarra A, Buxó M

Dosimetric Impact of Acuros XB Dose-to-Water and Dose-to-Medium Reporting Modes on Lung Stereotactic Body Radiation Therapy and Its Dependency on Structure Composition

Advances in Radiation Oncology, 2021, 6, 100722-100722 dx.doi.org/10.1016/j.adro.2021.100722
Romera-Martínez I, Muñoz-Montplet C, Jurado-Bruggeman D, Onsès-Segarra A, Fuentes-Raspall R, Buxó M, Vilanova JC

A Novel Device for Deep-Inspiration Breath Hold (DIBH): Results from a Single-Institution Phase 2 Clinical Trial for Patients with Left-Sided Breast Cancer

Practical Radiation Oncology, 2020, 10, 290-297 dx.doi.org/10.1016/j.prro.2020.02.004
Fuentes-Raspall R, Solans M, Auñon-Sanz C, Saez M, Marcos-Gragera R

Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20, 1628-1630 dx.doi.org/10.1007/s12094-018-1890-8
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F, GLIOCAT Group

Pseudoprogression as an adverse event of glioblastoma therapy.

CANCER MEDICINE, 2017, 6, 2858-2866 dx.doi.org/10.1002/cam4.1242
Fuentes-Raspall R, Solans M, Roca-Barceló A, Vilardell L, Puigdemont M, Del Barco S, Comas R, García-Velasco A, Astudillo A, Carmona-Garcia MC, Marcos-Gragera R

Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994-2013).

CANCER EPIDEMIOLOGY, 2017, 50, 1-8 dx.doi.org/10.1016/j.canep.2017.07.005

Formulari de contacte

About IDIBGI!

menu